

学术搜索

找到约 448 条结果 (用时0.04秒)

文章

我的图书馆

时间不限

2015以来

2014以来

2011以来

自定义范围...

按相关性排序

按日期排序

搜索所有网页

中文网页

英语网页

☒ 包括专利☒ 包含引用☐ 创建快讯[\[HTML\] Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma](#)wiley.com 中的 [\[HTML\]](#)H Shirakawa, H Suzuki, M Shimomura... - *Cancer* ..., 2009 - Wiley Online Library

... The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma ...

Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications ... Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early ...

被引用次数: 132 相关文章 所有 5 个版本 引用 保存

[Novel advancements in the management of hepatocellular carcinoma in 2008](#)JM Llovet, J Bruix - *Journal of hepatology*, 2008 - Elsevier

... Clinical trials; Survival; Molecular targeted therapies; Sorafenib. ... In Western countries and Japan, hepatitis C virus (HCV) infection is the main risk factor, together with other ... attempted to identify markers of early HCC, such as heat shock protein 70 (HSP70), Glypican-3 (GPC3) [17 ...

被引用次数: 713 相关文章 所有 6 个版本 引用 保存

[Glypican-3: a new target for cancer immunotherapy](#)M Ho, H Kim - *European Journal of Cancer*, 2011 - Elsevier

... Schematic of the glypican-3 (GPC3) protein. ... survival rate than GPC3-negative HCC patients, GPC3 expression is correlated with poor prognosis in HCC. ... patient studies from various human risk populations including specific clinicopathological features and prognostic values is ...

被引用次数: 69 相关文章 所有 7 个版本 引用 保存

[\[HTML\] Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall ...](#)aacrjournals.org 中的 [\[HTML\]](#)Y Sawada, T Yoshikawa, D Nobuoka, H Shirakawa... - *Clinical Cancer* ..., 2012 - AACR

... adequate antitumor efficacy in clinical trials in patients with advanced HCC (7-9). The carcinoembryonic antigen glypican-3 (GPC3) is an ... HCC because it is specifically overexpressed in HCC (72%-81%) and correlates with a poor prognosis (10-14). ... Prognostic factors of OS. ...

被引用次数: 72 相关文章 所有 5 个版本 引用 保存

[Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers](#)aacrjournals.org 中的 [\[HTML\]](#)K Imai, S Hirata, A Irie, S Senju, Y Ikuta... - *Clinical Cancer* ..., 2008 - AACR

... of esophageal cancer and hepatocellular carcinoma, respectively, and we have started a clinical trial of glypican-3 peptide-based ... A few studies have reported the up-regulation of CDH3 as a factor in the aggressive biological behavior and poor prognosis in breast (26-28 ...

被引用次数: 62 相关文章 所有 5 个版本 引用 保存

Name of journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 19904

Manuscript Type: TOPIC HIGHLIGHT

2015 Advances in Hepatocellular Carcinoma

Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma

Haruyama Y *et al.* Glypican-3 in HCC management

Yukihiro Haruyama, Hiroaki Kataoka

Yukihiro Haruyama, ²Hiroaki Kataoka, Section of Oncopathology and Regenerative Biology, Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan

Author contributions: Haruyama Y and Kataoka H contributed equally to this work; Haruyama Y and Kataoka H designed the review style, reviewed literatures and wrote the paper.

Supported by Collaborative Research Fund from Chugai Pharmaceutical Co. (to Haruyama Y); and Grant-in-Aid from The Ministry of Education, Culuture, Sports, Science and Technology, Japan, No. 24390099 (to Kataoka H).

Conflict-of-interest statement: Kataoka H receives collaborative research funding from Chugai Pharmaceutical Co. Haruyama Y declares ¹no potential conflicts of interest with respect to this article.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Match Overview

1	Internet 98 words crawled on 30-Mar-2015 www.wjgnet.com	1%
2	CrossCheck 57 words Ishida, Yo-ichi. "Functional foods effective for hepatitis C: ... entification of oligomeric proanthocyanidin and its action m	1%
3	CrossCheck 46 words Haruyama, Yukihiro, Kenji Yorita, Tetsuji Yamaguchi, Sachi ko Kitajima, Jun Amano, Toshihiko Ohtomo, Akinobu Ohno,	1%
4	CrossCheck 36 words Hirotake Takai. "The expression profile of glypican-3 and ... relation to macrophage population in human hepatocellular	<1%
5	Internet 23 words crawled on 09-Oct-2009 jcb.rupress.org	<1%

学术搜索

找到约 512 条结果 (用时0.07秒)

文章

我的图书馆

时间不限

2015以来

2014以来

2011以来

自定义范围...

按相关性排序

按日期排序

搜索所有网页

中文网页

简体中文网页

☒ 包括专利

☒ 包含引用

☐ 创建快讯

小提示: 只搜索中文(简体)结果, 可在 学术搜索设置 指定搜索语言

[HTML] Glypican - 3 expression is correlated with poor prognosis in hepatocellular carcinoma wiley.com 中的 [HTML]

H Shirakawa, H Suzuki, M Shimomura... - Cancer ..., 2009 - Wiley Online Library

... The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma ...

Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and

therapeutic implications ... Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early ...

被引用次数: 146 相关文章 所有 7 个版本 引用 保存

Novel advancements in the management of hepatocellular carcinoma in 2008

JM Llovet, J Bruix - Journal of hepatology, 2008 - Elsevier

... Clinical trials; Survival; Molecular targeted therapies; Sorafenib. ... In Western countries and Japan,

hepatitis C virus (HCV) infection is the main risk factor, together with other ... attempted to identify

markers of early HCC, such as heat shock protein 70 (HSP70), Glypican-3 (GPC3) [17 ...

被引用次数: 752 相关文章 所有 6 个版本 引用 保存

Glypican-3: a new target for cancer immunotherapy

M Ho, H Kim - European Journal of Cancer, 2011 - Elsevier

... Schematic of the glypican-3 (GPC3) protein. ... survival rate than GPC3-negative HCC patients,

GPC3 expression is correlated with poor prognosis in HCC. ... patient studies from various human

risk populations including specific clinicopathological features and prognostic values is ...

被引用次数: 75 相关文章 所有 10 个版本 引用 保存

[HTML] Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall ... aacrjournals.org 中的 [HTML]

Y Sawada, T Yoshikawa, D Nobuoka, H Shirakawa... - Clinical Cancer ..., 2012 - AACR

... adequate antitumor efficacy in clinical trials in patients with advanced HCC (7-9). The

carcinoembryonic antigen glypican-3 (GPC3) is an ... HCC because it is specifically overexpressed

in HCC (72%-81%) and correlates with a poor prognosis (10-14). ... Prognostic factors of OS. ...

被引用次数: 86 相关文章 所有 6 个版本 引用 保存

Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers aacrjournals.org 中的 [HTML]

K Imai, S Hirata, A Irie, S Senju, Y Ikuta... - Clinical Cancer ..., 2008 - AACR

... of esophageal cancer and hepatocellular carcinoma, respectively, and we have started a clinical

trial of glypican-3 peptide-based ... A few studies have reported the up-regulation of CDH3 as a



prognostic factor and an immunotherapeutic target in hepatocellular carcinoma



[网页](#) [图片](#) [新闻](#) [购物](#) [视频](#) [更多 ▾](#) [搜索工具](#)

找到约 10,700 条结果 (用时 0.72 秒)

Google 学术 : Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma

... with poor prognosis in hepatocellular carcinoma - Shirakawa - 被引用次数 : 147

... in the management of hepatocellular carcinoma in ... - Llovet - 被引用次数 : 754

Glypican-3: a new target for cancer immunotherapy - Ho - 被引用次数 : 75

Glypican3: a marker and a therapeutic target in ...

onlinelibrary.wiley.com/doi/10.1111/febs.12126/pdf ▾ [翻译此页](#)

作者 : J Filmus - 2013 - 被引用次数 : 44 - [相关文章](#)

... carcinoma; immunotherapy; tumor marker; Wnt signaling ... factors, including Wnts.

This regulation is based on the ability of glypicans to stimulate or ... Two therapeutic approaches for HCC that target GPC3 are currently being tested in phase II GPC3 expression is an independent predictor of poor prognosis in HCC.

Glypican-3: a new target for cancer immunotherapy

www.ncbi.nlm.nih.gov > ... > PubMed Central (PMC) ▾ [翻译此页](#)

作者 : M Ho - 2011 - 被引用次数 : 74 - [相关文章](#)

2010年11月26日 - Glypican-3: a new target for cancer immunotherapy ...

Hepatocellular carcinoma (HCC) remains a common malignant cancer worldwide. ...

GPC3 is also able to bind basic growth factors such as fibroblast growth factor 2 through HCC patients, GPC3 expression is correlated with poor prognosis in HCC.

Glypican-3 is overexpressed in human hepatocellular ...

www.researchgate.net/.../10692284_Glypican-3_is_overexpress... - [翻译此页](#)

Genes such as glypican-3 (GPC3), insulin-like growth factor 2, long-chain ...

Evaluation of GPC-3 as a diagnostic and immunotherapeutic target may be worthwhile